Exact Sciences
EXAS
EXAS was delisted on the 20th of March, 2026.
501 hedge funds and large institutions have $6.54B invested in Exact Sciences in 2022 Q2 according to their latest regulatory filings, with 52 funds opening new positions, 172 increasing their positions, 170 reducing their positions, and 100 closing their positions.
1% more repeat investments, than reductions
Existing positions increased: 172 | Existing positions reduced: 170
3.74% less ownership
Funds ownership: 96.16% → 92.41% (-3.7%)
10% less funds holding
Funds holding: 559 → 501 (-58)
23% less call options, than puts
Call options by funds: $63.3M | Put options by funds: $82.6M
43% less capital invested
Capital invested by funds: $11.5B → $6.54B (-$4.95B)
48% less first-time investments, than exits
New positions opened: 52 | Existing positions closed: 100
75% less funds holding in top 10
Funds holding in top 10: 8 → 2 (-6)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$134M |
| 2 |
State Street
Boston,
Massachusetts
|
+$38.4M |
| 3 |
Ameriprise
Minneapolis,
Minnesota
|
+$37.9M |
| 4 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$34.6M |
| 5 |
Capital World Investors
Los Angeles,
California
|
+$21.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$201M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$132M |
| 3 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$56.1M |
| 4 |
CC
Casdin Capital
New York
|
-$47.1M |
| 5 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$46.5M |
EXAS Hedge Fund Activity: Q2 2022 in Review
501 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in Exact Sciences (EXAS) for Q2 2022, worth a combined $6.54B — down 43% from $11.5B a quarter earlier.
Sellers outnumbered buyers: 100 funds closed out of EXAS and 52 opened new positions — a net loss of 48 holders — while 170 trimmed existing stakes and 172 added.
The largest buyer was Citadel Advisors, adding an estimated $134M. The largest seller was T. Rowe Price Associates, cutting an estimated $201M.
- 501 institutional investors held Exact Sciences (EXAS) as of Q2 2022, down from 559 in Q1 2022.
- Funds reported $6.54B of Exact Sciences stock for Q2 2022, down 43% quarter-over-quarter.
- 52 funds opened new Exact Sciences positions in Q2 2022 and 100 closed out, a net change of -48 holders.
- The largest Exact Sciences buyer in Q2 2022 was Citadel Advisors, an estimated $134M added.
- The largest Exact Sciences seller in Q2 2022 was T. Rowe Price Associates, an estimated $201M sold.
Based on aggregated 13F filings for Q2 2022.